The fattish obesity opportunity!
22/11/22 -"While diabetes has been Novo’s traditional stronghold, the firm is also the front-runner to grab a big share of the rapidly-growing obesity market. A combination of changing market dynamics, ..."
Pages
77
Language
English
Published on
22/11/22
You may also be interested by these reports :
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...
12/12/25
Eli Lilly’s Retatrutide grabbed headlines with c.29% weight-loss efficacy in late-stage trials for obese patients who also had knee osteoarthritis. ...
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...